Smither John W sold $41K of NAMS
Smither John W sold 1,600 shares of NewAmsterdam Pharma Co N.V. (NAMS) at $25.32 on 2026-09-04.
How this was made
The 30-second read
Why it matters
The filing provides a concrete datapoint on insider selling activity, but it does not include any accompanying operational or financial guidance change.
Market read
Traders may monitor insider activity for sentiment, but this specific sale is small and not tied to company performance in the text.
What to watch
Director sales can be driven by diversification, taxes, or pre-existing personal liquidity needs, and the disclosed value is small relative to typical market-moving thresholds.
Background
This is an SEC Form 4 insider transaction disclosure for NewAmsterdam Pharma (NAMS), reported by director John W. Smither.
Ticker impact
Form 4 shows director John W. Smither sold 1,600 shares of NewAmsterdam Pharma at $25.32 on 2026-09-04 for about $40.5K.
Limited, likely no sustained price impact unless paired with other disclosures.
The transaction size is modest ($40.5K) and the filing notes no 10b5-1 plan, but insider sales alone rarely drive material repricing without corroborating company news.
Market effects
No clear sector read-through from a single, small insider sale.
None.
None.
Counterpoint
The absence of a 10b5-1 plan could be interpreted by some traders as less routine selling, potentially increasing short-term scrutiny of management sentiment.
Key entities
- issuerNewAmsterdam Pharma Co N.V.
Subject of the Form 4 insider transaction disclosure.
- insiderJohn W. Smither
Director who sold 1,600 shares on 2026-09-04.
